VFS tab 25mg 30 pc

Description

Composition
Active substance:
1 tablet contains: lappaconitine hydrobromide with concomitant alkaloids (VFS *) (in terms of 100% substance) -25 mg.
Excipients:
Sucrose (sugar) or refined sugar, or sugar, starch potato (variety: “extra”), calcium stearate, sodium croscarmellose.
Description:
The tablets are round, biconvex shape, white.
Product form:
Tablets 25 mg.
At 10 or 30 tablets in blisters of PVC film and aluminum foil printed patent.
One, two, three or five contoured № 10 of cellular packages or one package № contour cell 30 together with instructions for medical application is placed in a pile of cardboard for packaging consumer.
Contraindications
Hypersensitivity, SA II blockade v., AV blockade II-III art. (Without pacemaker), blockade of right bundle branch block, juxtaposed to the blockade of one of the branches of the left leg, intraventricular conduction blockade, II-III CHF v., Severe hypotension, cardiogenic shock, severe renal / hepatic failure, pregnancy, lactation.
Carefully.
CHF (compensated), sick sinus syndrome, bradycardia, angle-closure glaucoma, prostatic hypertrophy, AV block I v., Disturbance of the conductivity of Purkinje fibers, blockade of a bundle branch block, electrolyte imbalance (hypokalemia, hyperkalemia, hypomagnesaemia) holding pacing (increase the risk of arrhythmias), liver and / or kidney failure, cardiomegaly, age 18 years (effectiveness and safety have not been studied).
Dosage
25 mg
Indications
Ventricular and supraventricular extrasystoles, ventricular and supraventricular tachycardia (including paroxysmal), paroxysm fibrillation or flutter (including the syndrome premature ventricular); myocardial infarction complicated by heart rhythm disturbances.
Interaction with other drugs
It enhances the effect of non-depolarizing muscle relaxants.
Inhibitors of microsomal oxidation increase the risk of toxic effects.
Inductors microsomal liver enzymes decrease efficiency.
Antiarrhythmic drugs, etc.. Classes increase the risk of arrhythmogenic action.
Overdose
Symptoms: has a small therapeutic breadth, so it can easily be severe intoxication (particularly, while the application of other antiarrhythmic agents): elongation of intervals PR and QT, expansion of the complex QRS, an increase in wave amplitude T, bradycardia, sinoatrial and AV blockade asystole, paroxysms polymorphic ventricular tachycardia, decreased myocardial contractility, marked reduction in blood pressure; dizziness, blurred vision, headache, gastrointestinal disorders.
Treatment: symptomatic; for the treatment of ventricular tachycardia is not applied antiarrhythmics of class IA or 1C; Sodium bicarbonate is capable of expanding to eliminate complex QRS, bradycardia and hypotension.
pharmachologic effect
Pharmacological group:
Antiarrhythmics.
Pharmacological properties:
Antiarrhythmic, local anesthetic, sedative.
Pharmacodynamics:
Class I antiarrhythmics, alkaloid aconite beloustogo. Blocks “fast” sodium channels of membranes of cardiomyocytes. It causes deceleration AV and intraventricular conduction, shortens the effective and functional refractory periods of the atria, AV node, bundle of His and Purkinje fibers, does not affect the duration of the interval QT, conductivity AV node in the anterograde direction, heart rate and blood pressure, myocardial contractility (the initial absence of phenomena CHF). Does not inhibit the automatism of the sinus node, it has no negative inotropic and hypotensive action. It has a moderate spasmolytic, coronary dilator, m-anticholinergic, local anesthetic and sedative effect.
When administered effect develops in 40-60 minutes, reaching a maximum after 4-5 hours and lasts 8 hours and more. The on / in the introduction antiarrhythmic effect appears after 15-20 minutes and lasts 6-8 hours (with a maximum of 2 hours).
Pharmacokinetics:
Bioavailability – 40%, has the effect of “first pass” through the liver, the volume of distribution at / in the introduction and ingestion – 42 and 690 l, respectively. Penetrates through the BBB.
One of the three major metabolites lowers blood pressure. T1 / 2 -. 1-1.2 h excreted by the kidneys.
Elongation T1 / 2 marked with prolonged use, CRF (2-3 times), liver cirrhosis (3-10 times).
Pregnancy and breast-feeding
Application VFS drug is not recommended during pregnancy. Perhaps the use of the drug only for health reasons, if the expected benefit to the mother outweighs the potential risk to the fetus / baby.
lappaconitine hydrobromide into breast milk is no data on the allocation. Use of the drug is not recommended during breast-feeding. If application during lactation is necessary, breast-feeding should be discontinued.
Conditions of supply of pharmacies
On prescription.
side effects
From the nervous system: dizziness, headache, diplopia, ataxia.
From the CCC: slowing intraventricular conduction arrhythmogenic effect, sinus tachycardia (with prolonged use), ECG changes: lengthening the interval P-Q, expansion of the complex QRS.
Other: allergic reactions, redness of skin.
special instructions
When the headache, dizziness, diplopia, reduce the dose. When the sinus tachycardia amid long reception shown beta-blockers (low dose).
Repeated parenteral administration is permitted only after 6 hours.
Purpose patients with AV blockade I v., SSS and decompensated heart failure is performed only in hospital and medical supervision during ECG monitoring. In the I trimester of pregnancy is appointed by “real life” testimony.
Effects on ability to drive vehicles and moving machinery.
In applying the drug should be taken when performing potentially hazardous activities that require attention and fast reactions (transportation management, work with moving machinery).
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside, after meals, with a small amount of water at room temperature, not milled.
Take one tablet (25 mg) every 8 hours in the absence of therapeutic effect – every 6 hours.
May increase to a single dose of 2 tablets (50 mg) every 6-8 hours. The maximum daily dose of 300 mg (12 tablets).
The duration of treatment and the correction mode (increasing dose) is determined by the doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist